Home → News → Clinical Trials → Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

May 2011

May 2

Treatment with NanoViricides FluCide Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference Cubist Pharmaceuticals' Antibiotic Programs Featured in 18 Abstracts at 21st ECCMID/27th ICC Joint Congress Xenon's XEN402 ointment significantly relieves pain in patients with post herpetic neuralgia Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002 Study Finds Desirudin Superior to Enoxaparin in Patients with Poor Kidney Function Undergoing Orthopedic Surgery Affinium Pharmaceuticals, Ltd., Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist Merck: Phase III Data for Investigational Glaucoma Treatment Tafluprost Presented at ARVO

May 3

QLT Announces Positive Results from Phase 1b Trial of QLT091001 in Subjects With Leber Congenital Amaurosis Discovery Labs' Aerosolized KL4 Surfactant Significantly Improves Lung Function and Survival in Established Model of Acute Lung Injury Rib-X Pharmaceuticals to Present Six Abstracts at 21st Annual ECCMID/ 27th Annual ICC Conference pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN in Diabetic Macular Edema FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study PRISTIQ (desvenlafaxine) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes Earlier Memory Loss Tied to Cardiovascular Risks & Alzheimer's Gene MedImmune to Present Eleven Abstracts on Influenza and Respiratory Syncytial Virus at the Annual Pediatric Academic Societies Meeting

May 4

Positive phase 2a results of Akebia's AKB-6548 for anemia Accentia Biopharmaceuticals Announces that Revimmune Autoimmune Disease Therapy is Featured in Peer-review Journal Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation Discovery Labs' Aerosolized KL4 Surfactant Program Data Presented at the Pediatric Academic Societies Annual Meeting Retrospective Analysis Explores LYSTEDA's Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding Plato BioPharma Presenting Poster at the American Thoracic Society Conference Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases A Little Belly Fat Can Double the Risk of Death in Coronary Artery Disease Patients

May 5

Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011 PolyMedix Announces Presentation of Four Abstracts at ECCMID 2011 Meeting Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors New Analysis Representing Largest Available Dataset Highlights Relative Safety of Lucentis (Ranibizumab) Compared to Unlicensed Intravitreal Avastin (Bevacizumab) Santhera Presents Positive Data from IONIA Open-Label Extension Study in Friedreich's Ataxia at the Fourth International Friedreich's Ataxia Scientific Conference ImmunoCellular Therapeutics Announces Updated Long-Term Disease-Free Survival Data from Phase I Study in Glioblastoma Millennium Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products Article in Current Opinion in Immunology Journal Declares Coming "Decade of DNA Vaccines" Santarus Announces Oral Presentations of Budesonide MMX Phase III Data at Digestive Disease Week Meeting Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference PolyMedix Presents Data on PMX-60056 at the American Heart Association ATVB-2011 Meeting The International Myeloma Foundation: Study Says Long-Term Maintenance Treatment Demonstrates 90% Overall Survival Rate Cempra Pharmaceuticals to Present Data on Solithromycin (CEM-101) and TAKSTA (CEM-102) at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC) Lymphoseek (Tilmanocept) Meets All Endpoints in NEO3-09 Phase 3 Study

May 9

Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study Durata Announces Supportive Data Analysis from Phase 3 Dalbavancin Trial at ECCMID Meeting New Data Reinforces Gardasil's Safety Profile 4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-ï?«B Pathways Tetraphase Presents Data Demonstrating Robust Activity and Dosing Flexibility of Intravenous and Oral Next-Generation Antibiotic Candidates Targeting Complicated, Multidrug-Resistant Pathogens Inovio Reports Long-Term Immune Responses from Cervical Dysplasia Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference Pfizer's Prevnar 13 Meets All Study Endpoints In Two Pivotal Phase 3 Trials In Adults Aged 50 And Older Presented Today Basilea's antibiotic BAL30072 shows activity against superbugs expressing the NDM-1 resistance factor Rib-X Pharmaceuticals Presents Data at ECCMID for Three Novel Classes of Broad-spectrum Antibiotic Compounds From the RX-04 Development Program Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting Rib-X Pharmaceuticals Presents Data at ECCMID Demonstrating Potent In Vitro Activity of Radezolid and Delafloxacin Against Resistant Strains of Gram-positive Bacteria Diamyd Medical: Diamyd Reports Initial Results from European Phase III Trial in Patients Newly Diagnosed with Type 1 Diabetes Chelsea Therapeutics Announces Approval to Open Enrollment Into 3.0 mg Arms of CH-4051 Phase II Trial in Rheumatoid Arthritis Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2011 Phase 2b Data Show Treatment With Stelara Induced and Maintained Clinical Response in Patients With Moderate to Severe Crohn's Disease Immusan Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic Forest and Almirall to Present Data from Phase III Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID Phase 3 Data

May 10

Durata Announces Antibiotic Surveillance Results for Dalbavancin Presented at ECCMID Meeting New analysis of Resolor data demonstrates acceleration of colonic transit time associated with improved bowel function in women with chronic constipation Top-line Results of the Pivotal Phase 3 Clinical Trial of TAK-085 in Japan for Treatment of Hypertriglyceridemia New Phase 3 Study Results Show Remicade Is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis Abbott's Humira (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study Data Presented at ECCMID Illustrate Risk Factors for Negative Outcomes in C. Difficile Patients GATTEX (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome Progesterone and TBI: Encore Therapeutics Inc. Completes Novel Commercially Enabling Progesterone Formulation for TBI Cimzia (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients Mayo Clinic Researchers Find New Treatment for Constipation Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma in ARVO 2011 Alkermes Presents Phase 2 Data of ALKS 37 in Late-Breaking Oral Session at Digestive Disease Week Meeting Meritage Pharma Reports Positive Phase 2b Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis Short Term Use of Painkillers Could Be Dangerous to Heart Patients

May 13

Long-Term Data on Avanafil to be Presented at the American Urological Association Annual Meeting MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference Theron Pharmaceuticals to Present at the American Thoracic Society Conference on May 15th, 2011 in Denver, Colorado Sickle Cell Anemia Drug Shown Safe and Effective for Infants and Toddlers, Improving Treatment Options DIFICID Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection DIFICID Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection Dificid Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection Micell Technologies Reports Preclinical Data for MiStent(TM) Drug-Eluting Coronary Stent to be Presented at EuroPCR

May 16

Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS) CEO of ARCA biopharma to Present Gencaro Development Programs at the European Society of Cardiology's Heart Failure Congress 2011 Novartis Studies Show Onbrez Breezhaler Plus Tiotropium Is More Effective Than Tiotropium Alone in Treatment of COPD Thallion's Phase II Shigatec Trial Proceeds to High Dose Cohort Long-Term Study Demonstrates Safety and Efficacy of Symbicort in African American Patients With Asthma No Increase in Severe Cardiovascular Events for Children, Adolescents Taking ADHD Medications Otsuka Pharmaceutical Co., Ltd. Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder H. Lundbeck A/S (DK) - Data from four clinical phase III studies of Lu AA21004 presented for the first time at the 2011 Annual Meeting of the American Psychiatric Association (APA) Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON or Crossed Over to FIRMAGON From Leuprolide Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia (certolizumab pegol) Stopping HIV Transmission with a Molecular Barrier MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference

May 17

Data Published in Journal of Clinical Oncology Highlights Significant Activity of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS) Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma Lantheus Announces New Cardiac PET Diagnostic Data at ICNC Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 2011 TIDES Summit Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense, at 2011 Annual ASCO Meeting Ajinomoto AminoScience to Speak and Exhibit at TIDES 2011 in Boston New Survey Reveals Most Americans Unaware of Gout Risk Factors, in the Dark About Connection to Diabetes, Kidney Disease, and Cardiac Problems Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting Denosumab May Prolong Metastasis-Free Survival in Men with High-Risk Prostate Cancer Watson Pharmaceuticals Announces New Research Showing Rapalfo (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Presentations by Vical and Collaborators at CMV/BetaHerpesvirus Workshop

May 18

Pfizer's Anti-TNF-Alpha Nanobody (ATN-103) Successfully Completes A Phase Ii Study And Demonstrates Clinical Proof-Of-Concept (Poc) In Patients With RA Amgen: Data Shows Xgeva Prevents Cancer from Spreading in Advanced Prostate Cancer Patients Firmagon (degarelix for injection) Extension Study Analysis Presented at AUA 2011 Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience Prenatal Use of Newer Antiepileptic Drugs Not Associated With Increased Risk of Major Birth Defects BIOTRONIK Announces Positive 6-Month Results for DREAMS, the Pioneering Drug-Eluting Absorbable Metal Scaffold Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva and Foradil in Patients with COPD ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society BIOTRONIK Announces Positive 6-Month Results for DREAMS, the Pioneering Drug-Eluting Absorbable Metal Scaffold Industry's First Hybrid Drug-Eluting Stent from BIOTRONIK Demonstrates Safety and Efficacy in First-in-Man Clinical Experience Randomized Study Combining L-Methylfolate With Antidepressant Shows Significant Boost in Patient Response

May 19

EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting RXi Pharmaceuticals Presents Updated NeuVax (E75) Data At ASCO PolyMedix PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity for Oral Mucositis Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting Urocidin Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C. Vildagliptin is significantly more effective in the management of Type 2 diabetes in South Asian Muslims fasting during Ramadan than the most commonly prescribed treatment Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings Omeros Announces Clinical Development Programs for OMS103HP and OMS302 Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual Meeting AMRI to Present Obesity Compound Phase I Clinical Results YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387 Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting CDG Therapeutics, Inc. Selected to Deliver Oral Presentation of ?First in Class, First in Human? Phase I Trial Results at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting Study Shows Sutro Biopharma's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients Heart Drugs Ineffective in Treating Pulmonary Arterial Hypertension Animal Results May Pave Way to Treating Rare Mitochondrial Diseases in Children Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma Study Characterizes Extractability Properties of Once-Daily Extended-Release Hydromorphone

May 20

Salix Pharmaceuticals Reviews Data Presentations at American Pain Society Annual Meeting Medtronic Resolute Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients Multiple Presentations Featuring QNEXA Data to be Presented at the European Congress on Obesity Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients Viagra Could Reduce Multiple Sclerosis Symptoms Use of naltrexone Reduces Inflammation in Crohn's Patients Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer Study Characterizes Extractability Properties of once-Daily Extended-Release Hydromorphone

May 23

Pacira Pharmaceuticals, Inc. Announces EXPAREL Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop Micromet to Report Blinatumomab Data at June Medical Conferences Spectrum Pharmaceuticals Announces ZEVALIN and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting PROLOR To Present Long-Acting Obesity and Multiple Sclerosis Drug Candidates at Leading Neuropeptide Conference Researchers to Present Nine Studies on Soliris (eculizumab) in Patients with PNH and aHUS at EHA Congress Vancomycin Continues to Dominate MRSA Treatment with up to 76 Percent of Surveyed Infectious Disease Specialists Indicating That They Use the Agent as First-Line Treatment for a Range of MRSA Infections Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights Led by Advances in Chemical Synthesis, Scripps Research Scientists Discover that a Rare Natural Product Has Potent Pain-Killing Properties

May 24

Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis Phase 3 Trial of Genasense in Advanced Melanoma Does Not Show Significant Increase in Overall Survival Biotie announces topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease Oxford BioMedica Announces Presentation of New Clinical Data from ProSavin Phase I/II Study in Parkinson's Disease New data support efficacy of Ruconest across all HAE attack locations New Clinical Trial Data Support the Use of Levemir in Children Aged Two to Five Years KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain ImmunoCellular Therapeutics to Present New Data from Phase I Study of ICT-107 in Glioblastoma Multiforme at ASCO 2011 Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo Study Finds Long-Term Treatment with TRIBENZOR was Effective and Well-Tolerated Regardless of Age, Race, or Diabetes Status Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop

May 25

PolyMedix Presents Antimicrobial Compound Data at Two Prestigious Scientific Meetings VBL Therapeutics To Present Updated Clinical Results for VB-111 at 2011 ASCO Annual Meeting Aileron Therapeutics to Present at Several Upcoming Peptide Drug Discovery Conferences New Four Year Stelara Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks By Up to 68% Vs. Steroid Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with Chronic Inflammatory Conditions Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) Amsterdam Molecular Therapeutics Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi Nearly 1 in 5 Young Adults Has High Blood Pressure, Study Shows Dangerous Side Effect of Common Drug Combination Discovered By Stanford Data Mining Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program Basilea reports positive results from first clinical phase I study with its novel antibiotic BAL30072 Ampio Pharmaceuticals, Inc. Completes Evaluation of Data From Phase III Clinical Trials of Zertane(TM) for Treatment of the Most Common Male Sexual Dysfunction, Premature Ejaculation Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics

May 26

BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting Zytiga Phase 3 Study Results re Metastatic Castration-Resistant Prostate Cancer Pfizer Announces Detailed Results Of ORAL Sync Showing Investigational Compound Tofacitinib Reduces Signs And Symptoms And Improves Physical Function In Patients With Moderate-To-Severe Active Rheumatoid Arthritis, With Results Seen As Early As Two Weeks Successful Proof of Concept for topical antimicrobial drug Lytixar: Completion of two Phase I/IIa clinical studies Synta Announces Publication of Results Showing Ganetespib (STA-9090) Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling Dynavax Completes Phase 3 Study of Heplisav CEL-SCI Corporation Study Shows LEAPS Dendritic Cell Therapy to Be Effective in Treating H1N1 Virus Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with Zytiga (abiraterone acetate) Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting Abbott Statement on Interim Study Results of AIM-HIGH Abbott Statement on Interim Study Results of AIM-HIGH NIH Stops Clinical Trial on Combination Cholesterol Treatment Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis

May 27

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model Abiraterone Acetate Significantly Improves Overall Survival of Patients with Post-Chemotherapy Metastatic Castration-Resistant Prostate Cancer RoActemra Could Change the Current Standard of Treatment for People With RA Arthritis Patients Taking Newer Treatments Do Not Have An Overall Increased Cancer Risk Omega-3 May Cut Risk of Artery Disease, Heart Attacks for Patients with Stents New Data for Cimzia (Certolizumab Pegol) Showed a Rapid Clinical Response Across a Broad Population of Rheumatoid Arthritis (RA) Patients SciFluor Life Sciences' Founders Author Review Article in Nature on Advances to Overcome Challenges Associated with Fluorination Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association

Clinical Trial Results Archive

2005

April

More News Resources

(web5)